In conclusion, the efforts to identify groups of relevant biomarkers in patients diagnosed with MS and treated with GA are beginning to show associations with response, such as the CD86, CLEC16A, CTSS, EOMES, MBP, FAS, TRBC1, IL1R1, IL12RB2, IL22RA2, PTPRT, PVT1, ALOX5AP, MAGI2, ZAK, RFPL3, UVRAG, SLC1A4, and HLA-DRB1*1501 gene polymorphisms that could be used in the future as predictive markers of response. This evidence concerns the gene CD86 and myeloid sarcoma.